← Leaderboards
Neeha Zaidi
Johns Hopkins University
$2,679,841
Attributed
$2,974,760
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,974,760 · 3
By mechanism
R37$1,318,180 · 1
K08$1,066,742 · 1
R01$589,838 · 1
Top collaborators
- Nilofer S. Azad1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Anirban Maitra$50,247,714
- Elizabeth Marion Jaffee$29,780,612
- Elana Fertig$10,275,542
- Michael G. Goggins$19,822,981
- Gloria Huei-Ting Su$8,620,087
Others in their field
Other Emerging Leaders on “Single-Cell Rna Sequencing”
- Evan Z Macosko · Broad Institute, Inc.$32,813,288
- Tomasz Nowakowski · University Of California, San Francisco$12,983,793
- Hemali Phatnani · New York University School Of Medicine$12,935,286
- Chongyuan Luo · University Of California Los Angeles$9,805,856
- Ansuman Satpathy · Stanford University$9,291,744
- Chun Jimmie Ye · Feinstein Institute For Medical Research$9,239,912
Research focus
Single-Cell Rna SequencingT-LymphocytePhenotypeSignal TransductionT Cell Receptor Repertoire SequencingT Cell ResponsePeptide VaccinesKras2 GenePeptidesResectedKrasg12dMutantCellsMemoryImmune Checkpoint InhibitorClinical TrialsImmuneExhaustionCd8-Positive T-LymphocytesImmunogenicityMutationPancreatic Ductal AdenocarcinomaArchitectureVaccines
Grant awards (8)
Mutant KRAS targeted vaccines for the interception of pancreatic cancer development$659,090
R37 · FY2025 · CA · contact PI
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer$589,838
R01 · FY2025 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer$179,834
K08 · FY2025 · CA · contact PI
Mutant KRAS targeted vaccines for the interception of pancreatic cancer development$659,090
R37 · FY2024 · CA · contact PI
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer$221,727
K08 · FY2024 · CA · contact PI
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer$221,727
K08 · FY2023 · CA · contact PI
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer$221,727
K08 · FY2022 · CA · contact PI
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer$221,727
K08 · FY2021 · CA · contact PI